Surviving a Merger: HBA Takes a Look

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

Berger joins Gilead with over 25 years of global drug development experience and will oversee the company’s virology, oncology, and inflammation portfolio.

For pharma manufacturers, the primary requirement for working with high-profile clients is matching their organizational level of urgency and organization.